[{"id":"b9dc9326-f8bf-456a-84d5-8c844765d88e","acronym":"M23-647","url":"https://clinicaltrials.gov/study/NCT05753501","created_at":"2023-03-03T15:01:38.988Z","updated_at":"2025-02-25T14:41:53.479Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","source_id_and_acronym":"NCT05753501 - M23-647","lead_sponsor":"AbbVie","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABBV-101"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/09/2023","start_date":" 06/09/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-14"}]